TeamDrive
RUS

Doctor Ryadom

www.drclinics.ru

Doctor Ryadom is a dynamically developed network of private clinics which was created in Moscow in 2014 by Team Drive and a group of private investors within public-private partnership with Moscow City Government. 

The first clinic started its work in April 2014 in a new, densely populous district in South-East of Moscow. 

In less than a year Doctor Ryadom opened in such areas of Moscow 10 modern, well-equipped, multidimensional clinics for adults and children. All clinics offer free reception of public using mandatory health insurance policy when patients with voluntary health insurance and on a fee basis are also serviced.  A wide range of modern technologies are fixed in the network of clinics Doctor Ryadom which are based on personalized medicine.

The project is actively developing: the company is planning to improve and expand the network of clinics and create clinical and diagnostic centers.

You can read all the details on Doctor Ruyadom website.

Media Center

  • 17 January 2018

    New tools for turning genes into drug factories

    Synthetic biologists have long dreamed of designing genetic circuits in the body that can produce drugs in response to environmental cues. But it’s been a challenging task. Now scientists at Rice University say they’ve created a toolkit of gene “promoters” that can turn genes on and off at command.

  • 17 January 2018

    FDA approves first treatment for breast cancer with a certain inherited genetic mutation

    The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.

  • 16 January 2018

    The coming of age of gene therapy: A review of the past and path forward

    After three decades of hopes tempered by setbacks, gene therapy—the process of treating a disease by modifying a person’s DNA—is no longer the future of medicine, but is part of the present-day clinical treatment toolkit. The Jan. 12 issue of the journal Science provides an in-depth and timely review of the key developments that have led to several successful gene therapy treatments for patients with serious medical conditions.

  • 16 January 2018

    Russia approves the mechanism for introducing the medicines into circulation

    A draft federal law on the introduction of medicinal products for human use into civil circulation was prepared by the Russian Ministry of Health. The bill proposes to establish a more effective legal regulation of relations associated with the elaboration, application and enforcement of requirements in the area of circulation of medicinal products for human use, namely, by establishing a mechanism for release control of medicines coming into the civil circulation in Russia.

Read more